Jiangbin Wu1, Kadiam C Venkata Subbaiah1, Li Huitong Xie2, Feng Jiang1,3, Eng-Soon Khor1, Deanne Mickelsen1, Jason R Myers4, Wai Hong Wilson Tang5, Peng Yao1,3,6,7. 1. From the Aab Cardiovascular Research Institute, Department of Medicine (J.W., K.C.V.S., F.J., E.-S.K., D.M., P.Y.), University of Rochester School of Medicine & Dentistry, New York. 2. Graduate Program in Genetics, Development and Stem Cells, Department of Biomedical Genetics (L.H.X.), University of Rochester School of Medicine & Dentistry, New York. 3. Biochemistry & Biophysics (F.J., P.Y.), University of Rochester School of Medicine & Dentistry, New York. 4. Genomics Research Center (J.R.M.), University of Rochester School of Medicine & Dentistry, New York. 5. Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T.). 6. The Center for RNA Biology (P.Y.), University of Rochester School of Medicine & Dentistry. 7. The Center for Biomedical Informatics (P.Y.), University of Rochester School of Medicine & Dentistry.
Abstract
RATIONALE: Increased protein synthesis of profibrotic genes is a common feature in cardiac fibrosis and heart failure. Despite this observation, critical factors and molecular mechanisms for translational control of profibrotic genes during cardiac fibrosis remain unclear. OBJECTIVE: To investigate the role of a bifunctional ARS (aminoacyl-tRNA synthetase), EPRS (glutamyl-prolyl-tRNA synthetase) in translational control of cardiac fibrosis. METHODS AND RESULTS: Results from reanalyses of multiple publicly available data sets of human and mouse heart failure, demonstrated that EPRS acted as an integrated node among the ARSs in various cardiac pathogenic processes. We confirmed that EPRS was induced at mRNA and protein levels (≈1.5-2.5-fold increase) in failing hearts compared with nonfailing hearts using our cohort of human and mouse heart samples. Genetic knockout of one allele of Eprs globally (Eprs+/-) using CRISPR-Cas9 technology or in a Postn-Cre-dependent manner (Eprsflox/+; PostnMCM/+) strongly reduces cardiac fibrosis (≈50% reduction) in isoproterenol-, transverse aortic constriction-, and myocardial infarction (MI)-induced heart failure mouse models. Inhibition of EPRS using a PRS (prolyl-tRNA synthetase)-specific inhibitor, halofuginone, significantly decreases translation efficiency (TE) of proline-rich collagens in cardiac fibroblasts as well as TGF-β (transforming growth factor-β)-activated myofibroblasts. Overexpression of EPRS increases collagen protein expression in primary cardiac fibroblasts under TGF-β stimulation. Using transcriptome-wide RNA-Seq and polysome profiling-Seq in halofuginone-treated fibroblasts, we identified multiple novel Pro-rich genes in addition to collagens, such as Ltbp2 (latent TGF-β-binding protein 2) and Sulf1 (sulfatase 1), which are translationally regulated by EPRS. SULF1 is highly enriched in human and mouse myofibroblasts. In the primary cardiac fibroblast culture system, siRNA-mediated knockdown of SULF1 attenuates cardiac myofibroblast activation and collagen deposition. Overexpression of SULF1 promotes TGF-β-induced myofibroblast activation and partially antagonizes anti-fibrotic effects of halofuginone treatment. CONCLUSIONS: Our results indicate that EPRS preferentially controls translational activation of proline codon rich profibrotic genes in cardiac fibroblasts and augments pathological cardiac remodeling. Graphical Abstract: A graphical abstract is available for this article.
RATIONALE: Increased protein synthesis of profibrotic genes is a common feature in cardiac fibrosis and heart failure. Despite this observation, critical factors and molecular mechanisms for translational control of profibrotic genes during cardiac fibrosis remain unclear. OBJECTIVE: To investigate the role of a bifunctional ARS (aminoacyl-tRNA synthetase), EPRS (glutamyl-prolyl-tRNA synthetase) in translational control of cardiac fibrosis. METHODS AND RESULTS: Results from reanalyses of multiple publicly available data sets of human and mouseheart failure, demonstrated that EPRS acted as an integrated node among the ARSs in various cardiac pathogenic processes. We confirmed that EPRS was induced at mRNA and protein levels (≈1.5-2.5-fold increase) in failing hearts compared with nonfailing hearts using our cohort of human and mouse heart samples. Genetic knockout of one allele of Eprs globally (Eprs+/-) using CRISPR-Cas9 technology or in a Postn-Cre-dependent manner (Eprsflox/+; PostnMCM/+) strongly reduces cardiac fibrosis (≈50% reduction) in isoproterenol-, transverse aortic constriction-, and myocardial infarction (MI)-induced heart failuremouse models. Inhibition of EPRS using a PRS (prolyl-tRNA synthetase)-specific inhibitor, halofuginone, significantly decreases translation efficiency (TE) of proline-rich collagens in cardiac fibroblasts as well as TGF-β (transforming growth factor-β)-activated myofibroblasts. Overexpression of EPRS increases collagen protein expression in primary cardiac fibroblasts under TGF-β stimulation. Using transcriptome-wide RNA-Seq and polysome profiling-Seq in halofuginone-treated fibroblasts, we identified multiple novel Pro-rich genes in addition to collagens, such as Ltbp2 (latent TGF-β-binding protein 2) and Sulf1 (sulfatase 1), which are translationally regulated by EPRS. SULF1 is highly enriched in human and mouse myofibroblasts. In the primary cardiac fibroblast culture system, siRNA-mediated knockdown of SULF1 attenuates cardiac myofibroblast activation and collagen deposition. Overexpression of SULF1 promotes TGF-β-induced myofibroblast activation and partially antagonizes anti-fibrotic effects of halofuginone treatment. CONCLUSIONS: Our results indicate that EPRS preferentially controls translational activation of proline codon rich profibrotic genes in cardiac fibroblasts and augments pathological cardiac remodeling. Graphical Abstract: A graphical abstract is available for this article.
Authors: Shuin Park; Sara Ranjbarvaziri; Fides D Lay; Peng Zhao; Mark J Miller; Jasmeet S Dhaliwal; Adriana Huertas-Vazquez; Xiuju Wu; Rong Qiao; Justin M Soffer; Christoph Rau; Yibin Wang; Hanna K A Mikkola; Aldons J Lusis; Reza Ardehali Journal: Circulation Date: 2018-09-18 Impact factor: 29.690
Authors: Marisa I Mendes; Mariana Gutierrez Salazar; Kether Guerrero; Isabelle Thiffault; Gajja S Salomons; Laurence Gauquelin; Luan T Tran; Diane Forget; Marie-Soleil Gauthier; Quinten Waisfisz; Desiree E C Smith; Cas Simons; Marjo S van der Knaap; Iris Marquardt; Aida Lemes; Hanna Mierzewska; Bernhard Weschke; Wolfgang Koehler; Benoit Coulombe; Nicole I Wolf; Geneviève Bernard Journal: Am J Hum Genet Date: 2018-03-22 Impact factor: 11.025
Authors: Mark S Sundrud; Sergei B Koralov; Markus Feuerer; Dinis Pedro Calado; Aimee Elhed Kozhaya; Ava Rhule-Smith; Rachel E Lefebvre; Derya Unutmaz; Ralph Mazitschek; Hanspeter Waldner; Malcolm Whitman; Tracy Keller; Anjana Rao Journal: Science Date: 2009-06-05 Impact factor: 47.728
Authors: Charles R Holst; Hani Bou-Reslan; Bryan B Gore; Karen Wong; Deanna Grant; Sreedevi Chalasani; Richard A Carano; Gretchen D Frantz; Marc Tessier-Lavigne; Brad Bolon; Dorothy M French; Avi Ashkenazi Journal: PLoS One Date: 2007-06-27 Impact factor: 3.240
Authors: Jiangbin Wu; Kadiam C Venkata Subbaiah; Feng Jiang; Omar Hedaya; Amy Mohan; Tingting Yang; Kevin Welle; Sina Ghaemmaghami; Wai Hong Wilson Tang; Eric Small; Chen Yan; Peng Yao Journal: EMBO Mol Med Date: 2020-12-28 Impact factor: 12.137
Authors: Anissa A Widjaja; Sivakumar Viswanathan; Dong Jinrui; Brijesh K Singh; Jessie Tan; Joyce Goh Wei Ting; David Lamb; Shamini G Shekeran; Benjamin L George; Sebastian Schafer; David Carling; Eleonora Adami; Stuart A Cook Journal: Front Mol Biosci Date: 2021-09-28